Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mosquito Insecticide Resistance Ontology Resource Report Resource Website |
Mosquito Insecticide Resistance Ontology (RRID:SCR_003864) | MIRO | ontology, data or information resource, controlled vocabulary | Application ontology for entities related to insecticide resistance in mosquitos | obo | is listed by: BioPortal | nlx_157486 | SCR_003864 | 2026-08-15 11:22:39 | 0 | |||||||||
|
EU-AIMS Resource Report Resource Website 1+ mentions |
EU-AIMS (RRID:SCR_003861) | EU-AIMS | organization portal, data or information resource, consortium, portal | Consortium aiming to generate tools that will enhance understanding of autism spectrum disorders (ASD) and pave the way for the development of new, safe and effective treatments for use in both children and adults. For example, the team will gather samples from people bearing certain mutations associated with ASD; this will pave the way for the generation of cell lines that can be used to test treatments. Elsewhere, the researchers will advance the use of brain scans as a tool to boost ASD drug discovery and also identify which people with ASD might respond best to a given drug. The project will also create a pan-European network of clinical sites. As well as making it easier to run clinical trials, this network will create an interactive platform for those with ASD and professionals. By the end of the 5 year project they expect to provide novel validated cellular assays, animal models, new fMRI methods with dedicated analysis techniques, new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. They will provide a research network that can rapidly test new treatments in man. These tools should provide their EFPIA partners with an added competitive advantage in developing new drugs for ASD. | basic science, tool development, child, adult human, young human, treatment, diagnose, symptom, clinical, cell line, drug, drug discovery, neuroimaging, mutation, clinical trial, medicine |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Pfizer Animal Genetics is related to: King's College London; London; United Kingdom is related to: Birkbeck University of London; London; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: CEA; Gif sur Yvette; France is related to: European Molecular Biology Laboratory is related to: University College London; London; United Kingdom is related to: Pasteur Institute is related to: Karolinska Institute; Stockholm; Sweden is related to: Max-Planck-Gesellschaft is related to: Biomedical University Campus of Rome; Rome; Italy is related to: University of Basel; Basel; Switzerland is related to: Ulm University; Baden-Wurttemberg; Germany is related to: University of Cambridge; Cambridge; United Kingdom is related to: Autism Speaks is related to: GABO:mi is related to: deCODE genetics is related to: Noldus has parent organization: Roche |
Innovative Medicines Initiative ; EFPIA |
nlx_158184 | SCR_003861 | European Autism Interventions - A Multicentre Study for Developing New Medications, European Autism Interventions | 2026-08-15 11:22:37 | 2 | |||||||
|
Roslin Cells Resource Report Resource Website 1+ mentions |
Roslin Cells (RRID:SCR_003857) | Roslin Cells | commercial organization | Organization that supplies undifferentiated, clinical grade, human pluripotent stem cell lines to the life science community, and works with academic, clinical and commercial colleagues to enable and facilitate the use of these high grade cells in the development of new reagents, drugs and cellular therapeutics. They also seek to drive the economic development of the stem cell sector in Scotland. Their products can act as a valuable tool in supporting clients' drug discovery, development and clinical research programmes. | pluripotent stem cell, induced pluripotent stem cell, cell therapy, embryonic stem cell line, clinical grade |
is listed by: One Mind Biospecimen Bank Listing is parent organization of: EBiSC |
nlx_158181 | SCR_003857 | Roslin Cells Ltd | 2026-08-15 11:22:43 | 2 | ||||||||
|
EARIP Resource Report Resource Website |
EARIP (RRID:SCR_003854) | EARIP | organization portal, data or information resource, consortium, portal | Consortium that convenes asthma experts from across Europe to define research gaps to reduce the impact of asthma. The project activities range from basic cell science research, to assessing and improving European healthcare systems. Their activities include workshops, prioritization exercises, consensus strategies, and the development and publication of a set of recommendations about what's needed to reduce asthma deaths and hospitalizations. The eventual goal is to have a comprehensive R&D roadmap for asthma. EARIP will target a number of asthma research areas to ensure a comprehensive overview of all current research strategies from across Europe is included in the project road map. These include: * Research into biological targets, aiming to discover new targets and better define the role of existing biological targets * Identify new systems, models and tools for phenotypic stratification * Develop better and more efficient healthcare systems across Europe * Define and develop new diagnostic tools * Assess and improve patient self-management systems and provide suggestions for how these can be developed * Identify how to establish a European Innovation Partnership (EIP) for the management of asthma * Establish a European research network of clinical asthma research facilities | biomarker, biological target, tool development, clinical, basic research |
is listed by: Consortia-pedia is related to: Imperial College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: European Federation of Allergy and Airways Diseases Patients Associations is related to: European Lung Foundation is related to: University of Athens; Athens; Greece is related to: University of Southampton; Southampton; United Kingdom is related to: Swiss Institute of Allergy and Asthma Research is related to: University of Lodz; Lodz; Poland has parent organization: Asthma UK |
European Union FP7-Health Programme 602077 | nlx_158171 | SCR_003854 | European Asthma Research and Innovation Partnership, European Asthma Research and Innovation Partnership (EARIP) | 2026-08-15 11:22:37 | 0 | |||||||
|
Mouse Gross Anatomy and Development Ontology Resource Report Resource Website |
Mouse Gross Anatomy and Development Ontology (RRID:SCR_003891) | EMAP | ontology, data or information resource, controlled vocabulary | A structured controlled vocabulary of stage-specific anatomical structures of the mouse (Mus). | obo | is listed by: BioPortal | nlx_157488 | SCR_003891 | 2026-08-15 11:22:37 | 0 | |||||||||
|
PEAR Resource Report Resource Website 500+ mentions |
PEAR (RRID:SCR_003776) | PEAR | software resource | Software for an ultrafast, memory-efficient and highly accurate pair-end read merger. It is fully parallelized and can run with as low as just a few kilobytes of memory. | next-generation sequencing, sequence analysis |
is listed by: OMICtools has parent organization: Heidelberg Institute for Theoretical Studies; Heidelberg; Germany |
PMID:24142950 | OMICS_00674 | SCR_003776 | Pair-end read merger, PEAR: Pair-end read merger | 2026-08-15 11:22:40 | 914 | |||||||
|
Lhasa Limited Resource Report Resource Website 10+ mentions |
Lhasa Limited (RRID:SCR_003775) | Lhasa | funding resource, portal, data or information resource, software resource, community building portal | A not-for-profit membership organization and educational charity that facilitates collaborative data sharing projects in the pharmaceutical, cosmetics and chemistry-related industries specializing in the development of expert computer systems for toxicity and metabolism prediction. They provide a number of extensive and continually updated knowledge bases and the software needed to interrogate them. Its charitable aims include the sponsorship of activities that advance scientific knowledge and understanding and they regularly support computational chemistry events and initiatives that are of interest to Lhasa Limited members and the wider scientific community. All applications for sponsorship will be considered on their individual merits. | data sharing, pharmaceutical, cosmetic, chemistry, toxicity prediction, metabolism, toxicity, metabolism prediction, prediction, database, in silico, computational chemistry, computer system | is related to: MIP-DILI | Membership required, For sale | nlx_158058 | SCR_003775 | Lhasa Ltd. | 2026-08-15 11:22:37 | 17 | |||||||
|
Electro Scientific Industries Resource Report Resource Website |
Electro Scientific Industries (RRID:SCR_003895) | ESI | commercial organization | A high technology company that is a developer and supplier of photonic and laser systems for microelectronics manufacturers. They manufacture a variety of products for testing and repairing equipment, and particularly products designed for use by manufacturers of other high-tech products. These include laser trimming systems. (Adapted from Wikipedia) | microengineering, electronics, semiconductor, testing, repair, laser trimming system, photonic, laser, microelectronics | is related to: ONE Study | nlx_158228 | SCR_003895 | Electro Scientific Industries Inc. | 2026-08-15 11:22:37 | 0 | ||||||||
|
IAESTE Resource Report Resource Website |
IAESTE (RRID:SCR_003773) | IAESTE | training resource | An independent, non-profit and non-political student exchange organization that provides students in technical degrees (primarily Science, Engineering and the applied arts) with paid, course-related, training abroad and employers with highly skilled, highly motivated trainees, for long or short term projects. | student, international | has parent organization: Imperial College London; London; United Kingdom | nlx_158047 | SCR_003773 | International Association for the Exchange of Students for Technical Experience | 2026-08-15 11:22:40 | 0 | ||||||||
|
Inserm Transfert Resource Report Resource Website |
Inserm Transfert (RRID:SCR_003808) | commercial organization | A private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). It manages European and International research projects, supports large scale projects in epidemiology and public health. It has run a proof of concept fund. The company is also committed to seed financing in the biotech sector, through its dedicated seed fund company Inserm Transfert Initiative. www.inserm-transfert.fr | technology transfer, epidemiology, public health |
is related to: AgedBrainSYSBIO has parent organization: National Institute of Health and Medical Research; Rennes; France is parent organization of: AgedBrainSYSBIO |
nlx_158128, grid.14498.30 | https://ror.org/01wftfc57 | SCR_003808 | Inserm-Transfert SA, Inserm Transfert SA | 2026-08-15 11:22:38 | 0 | ||||||||
|
TRANSFoRm Clinical Research Information Model Resource Report Resource Website |
TRANSFoRm Clinical Research Information Model (RRID:SCR_003889) | CRIM | data or information resource, report, standard specification, narrative resource | A clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting. | clinical, randomized clinical trial, clinical trial, primary care, genetic, clinical research, electronic health record, model, interoperability |
uses: Clinical Data Interchange Standards Consortium is used by: TRANSFoRm Data Integration Models has parent organization: TRANSFoRm |
nlx_158219 | SCR_003889 | Clinical Research Information Model | 2026-08-15 11:22:40 | 0 | ||||||||
|
Minimum Information About a Simulation Experiment Resource Report Resource Website 1+ mentions |
Minimum Information About a Simulation Experiment (RRID:SCR_003800) | MIASE | data or information resource, narrative resource, standard specification | A set of guidelines (community effort) suitable for use with any structured format for simulation experiments to identify the Minimal Information About a Simulation Experiment necessary to enable the reproducible simulation experiments. The Guidelines list the information that a modeller needs to provide to enable the execution and reproduction of a numerical simulation experiment, derived from a given set of quantitative models. MIASE is designed to help modelers and software tools to exchange their simulation settings and to foster collaboration. In 2011, he MIASE guidelines were accepted by researchers from 19 different institutes. | simulation |
is used by: Simulation Experiment Description Markup Language is listed by: Minimum Information for Biological and Biomedical Investigations |
PMID:21552546 | nlx_158097 | SCR_003800 | MIASE Guidelines | 2026-08-15 11:22:38 | 2 | |||||||
|
TRANSFoRm Resource Report Resource Website 50+ mentions |
TRANSFoRm (RRID:SCR_003888) | TRANSFoRm | organization portal, data or information resource, consortium, portal | Project to develop a ''rapid learning healthcare system'' driven by advanced computational infrastructure that can improve both patient safety and the conduct and volume of clinical research in Europe. Three carefully chosen clinical ''use cases'' will drive, evaluate and validate the approach to the ICT (information and communications technology) challenges. The project will build on existing work at international level in clinical trial information models (BRIDG and PCROM), service-based approaches to semantic interoperability and data standards (ISO11179 and controlled vocabulary), data discovery, machine learning and electronic health records based on open standards (openEHR). TRANSFoRm will extend this work to interact with individual eHR systems as well as operate within the consultation itself providing both diagnostic support and support for the identification and follow up of subjects for research. The approach to system design will be modular and standards-based, providing services via a distributed architecture, and will be tightly linked with the user community. Four years of development and testing will end with a fifth year that will be dedicated to summative validation of the project deliverables in the Primary Care setting. In order to support patient safety in both clinical and research settings, significant ICT challenges need to be overcome in the areas of interoperability, common standards for data integration, data presentation, recording, scalability, and security., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | clinical, interoperability, healthcare system, healthcare, electronic health record, clinical data, metadata standard, aggregator |
has parent organization: King's College London; London; United Kingdom is parent organization of: TRANSFoRm Clinical Data Integration Model is parent organization of: TRANSFoRm Clinical Research Information Model is parent organization of: TRANSFoRm Data Integration Models |
European Union FP7 247787 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158218 | SCR_003888 | Translational Research and Patient Safety In Europe | 2026-08-15 11:22:37 | 60 | ||||||
|
PREDECT Resource Report Resource Website 1+ mentions |
PREDECT (RRID:SCR_003883) | PREDECT | organization portal, data or information resource, consortium, portal | Project that aims to create more appropriate in vitro platforms for target validation and drug discovery for breast, prostate and lung cancers. Laboratory platforms to validate whether target modulation would provide a clinical benefit are usually highly reductionist, often using long-established cell lines growing in 2 dimensions in vitro. These models do not reflect the complexity and heterogeneity of a tumor in situ, where biochemical pathways are wired with connections to the complex tumor environment provided by the stroma. PREDECT has the goal of comparing the pathological and molecular profiles of novel in vitro platforms with those of human tumors. Because obtention of clinical material presents both logistics and quality problems for ongoing and intense studies of target validation, PREDECT aims to use material from genetically engineered mouse models, and some advanced xenografts, whose pathology and molecular profiles closely match cohorts of human tumors. PREDECT hopes to provide more appropriate in vitro platforms both for target validation and subsequent preclinical studies which will replace a current cascade of tests which are poorly predictive of clinical activity. The project is expected to shift paradigms in cell biology as well as in preclinical target validation where it should permit greater predictivity of drug efficacy in patient cohorts. | drug, oncology, drug development, basic research, in vitro, xenograft, breast, prostate, lung, pre-clinical, target validation, drug discovery |
is listed by: Consortia-pedia is related to: Roche is related to: Orion is related to: sigma-tau is related to: Janssen Research and Development is related to: AbbVie is related to: Institute of Cancer Research is related to: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland is related to: VTT Technical Research Centre of Finland is related to: University of Helsinki; Helsinki; Finland is related to: University of Tartu; Tartu; Estonia is related to: Biomedicum Genomics is related to: Oncotest is related to: Institute of Experimental Biology and Technology; Oeiras; Portugal is related to: Cardiff University; Wales; United Kingdom has parent organization: University of Helsinki; Helsinki; Finland |
Innovative Medicines Initiative ; EFPIA |
nlx_158212 | SCR_003883 | Preclinical evaluation of drug efficacy in common solid tumours, Predect New models for preclinical evaluation of drug efficacy in common solid tumours | 2026-08-15 11:22:43 | 8 | |||||||
|
PharmaCog Resource Report Resource Website 10+ mentions |
PharmaCog (RRID:SCR_003878) | PharmaCog | organization portal, data or information resource, consortium, portal | Project aiming to tackle bottlenecks in Alzheimer''''s disease research and drug discovery by developing and validating new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. They will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. By bringing together databases of previously conducted clinical trials and combining the results from blood tests, brain scans and behavioral tests, the scientists will develop a ''''signature'''' that gives more accurate information on the progression of the disease and the effect of candidate drugs than current methods do. The scientists will conduct parallel studies in laboratory models, healthy volunteers and patients in order to better predict good new drugs as early as possible. This will enable them, for instance, to find out how memory loss in Alzheimer''''s disease can be simulated in healthy volunteers, for example with sleep deprivation or drugs that temporarily affect the memory, in order to test the effect of candidate-medicines early in the drug development process. | drug, biomarker, drug discovery, model, tool development, drug development, medicine, clinical, pre-clinical, pharmacology, disease progression, cognitive impairment |
is listed by: Consortia-pedia is related to: Merck is related to: Janssen Research and Development is related to: Roche is related to: Eisai is related to: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France is related to: Alzheimer Europe is related to: French National Center for Scientific Research is related to: Greek Association of Alzheimers Disease and Related Disorders is related to: August Pi i Sunyer Biomedical Research Institute; Barcelona; Spain is related to: National Institute of Health and Medical Research; Rennes; France is related to: Mario Negri Institute for Pharmacological Research; Milan; Italy is related to: University of Murcia; Murcia; Spain is related to: Catholic University of the Sacred Heart; Milan; Italy is related to: University of Foggia; Foggia; Italy is related to: University of Genoa; Genoa; Italy is related to: University of Perugia; Perugia; Italy is related to: University of Verona; Verona; Italy is related to: University of Leipzig; Saxony; Germany is related to: Lille 2 University of Health and Law; Lille; France is related to: University of Exeter; Exeter; United Kingdom is related to: Innovative Concepts in Drug Development is related to: AlzProtect is related to: Qualissima is related to: Exonhit Therapeutics is related to: University of Bristol; Bristol; United Kingdom is related to: European Medicines Agency has parent organization: Lille 2 University of Health and Law; Lille; France has parent organization: Alzheimer Europe has parent organization: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France |
Innovative Medicines Initiative 115009; EFPIA |
nlx_158206 | SCR_003878 | Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, Pharma-Cog | 2026-08-15 11:22:43 | 13 | |||||||
|
Patients to Trials Consortium Resource Report Resource Website |
Patients to Trials Consortium (RRID:SCR_003877) | Patients2Trials Consortium | service resource, portal, people resource, data or information resource, community building portal, consortium, organization portal | A three-member pharmaceutical industry consortium that aims to provide a new platform to improve access to information about clinical trials for patients and providers. The platform aims to enhance the existing clinicaltrials.gov by providing more detailed and patient-friendly information about available trials and embedding a machine-readable target health profile to improve the ability of healthcare software to match individual health profiles with applicable clinical trials. Using clinicaltrials.gov as its foundation and Eli Lilly''''s Application Programming Interface (API), the consortium is focused on creating an open platform to make this data more amenable to patients and providers, as well as creating an opportunity to integrate a patient''''s electronic health record into the clinical trial matching service. This feature will allow patients to search for trials using their own Blue Button data. The following features are planned add-ons to clinicaltrials.gov: * Target Profile is a machine readable query, that can be executed against an electronic file (or record) with patient health data such as an Electronic Health Record (EHR), an Electronic Medical Record (EMR) or Personally Controlled Health Record (PCHR) * Augmented Content is public, IRB approved information about the study that has not been published on clinicaltrials.gov, and that is shared with / targeted for patients with a matching Target Profile. The following are the incremental goals of the consortium: * Advancement of the Lilly API platform to support read/write interaction and additional data objects and information. * The initial 3 sponsor organizations - Lilly, Pfizer and Novartis - will upload Target Profiles for a select set of clinical trials. A Target Profile is a machine interpretable description of the characteristics of patients who may qualify for that trial i.e. a query that can be executed against a patient''''s electronic health record or personal health record. Additionally, sponsors of clinical research studies will also be able to upload Augmented Content to the Lilly Platform to supplement information on clinicaltrials.gov with additional, patient-focused information about the study, e.g., a study brochure and practical information on how to contact investigational sites. * A matching service, developed by Corengi, will compare Target Profiles to a de-dentified personally controlled health record (PCHR), represented by patient''''s Blue Button Plus CCDA XML document. * Integration into a patient community platform from Avado for providing the patient PCHR and presenting the results of the match service. The patient will be able to explore the respective matching studies for additional information and next steps such as contacting a nearby investigator clinic or hospital. The first demo of the prototype was made available on June 2014, built on a database of anonymized patient health records from different clinical research studies sponsored by Lilly, Novartis, and Pfizer. Other website: http://portal.lillycoi.com/ | drug development, tool development, clinical trial, clinical, patient profile, clinical research study, health record, platform, database |
uses: ClinicalTrials.gov is listed by: Consortia-pedia is related to: Pfizer Animal Genetics is related to: Corengi |
Open unspecified license, Public | nlx_158205 | SCR_003877 | p2t consortium | 2026-08-15 11:22:40 | 0 | |||||||
|
Chevron Corporation Resource Report Resource Website 1+ mentions |
Chevron Corporation (RRID:SCR_003794) | Chevron, CVX | commercial organization | An American multinational energy corporation headquartered in San Ramon, California, and active in more than 180 countries, that is engaged in every aspect of the oil, gas, and geothermal energy industries, including exploration and production; refining, marketing and transport; chemicals manufacturing and sales; and power generation. Chevron is one of the world's largest oil companies; as of 2013, it ranked third in the Fortune Global 500-2014 list of the world's largest companies. (Adapted from Wikipedia) | oil, gas, geothermal energy, chemicals manufacturing, power generation | Crossref funder ID: 100004366, grid.450626.3, ISNI: 0000 0004 0599 8199, Wikidata: Q319642, nlx_158090 | https://ror.org/02jfa8730 | SCR_003794 | Chevron Corp., Chevron Corp | 2026-08-15 11:22:38 | 1 | ||||||||
|
Charles River Laboratories Resource Report Resource Website 10000+ mentions |
Charles River Laboratories (RRID:SCR_003792) | CRL | biomaterial supply resource, material resource, organism supplier | Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia) | RIN, Resource Information Network, pre-clinical, clinical, pharmaceutical, medical device, biotechnology, drug, drug discovery, RRID Community Authority |
is listed by: Resource Information Network is related to: Oncotest works with: International Mouse Strain Resource |
SCR_013551, grid.452317.6, nlx_158088, nif-0000-00462, Wikidata: Q28974283 | https://ror.org/01tasya06 | SCR_003792 | Charles River Laboratories Inc., Charles River, Charles River Laboratories International Inc. | 2026-08-15 11:22:41 | 11510 | |||||||
|
BioReliance Resource Report Resource Website 50+ mentions |
BioReliance (RRID:SCR_003791) | BREL | commercial organization | Company that provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production. | testing, manufacturing, pharmaceutical, biopharmaceutical |
has parent organization: Sigma-Aldrich is parent organization of: BioReliance Biorepository |
nlx_158085 | SCR_003791 | BioReliance Corporation, BioReliance Corp. | 2026-08-15 11:22:37 | 62 | ||||||||
|
Minimal Standard Terminology of Digestive Endoscopy - French Resource Report Resource Website |
Minimal Standard Terminology of Digestive Endoscopy - French (RRID:SCR_003830) | MSTDE-FRE | ontology, data or information resource, controlled vocabulary | Metathesaurus Version of Minimal Standard Terminology Digestive Endoscopy, French Translation, 2001 | umls | is listed by: BioPortal | nlx_157484 | SCR_003830 | Minimal Standard Terminology of Digestive Endoscopy French | 2026-08-15 11:22:38 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
